Molybdenum-Copper Antagonism In Metalloenzymes And Anti-Copper Therapy
Biplab K Maiti1, Isabel Moura2, José J G Moura2
1Department of Chemistry, School of sciences, Cluster University of Jammu, Canal Road, Jammu, 180001, India.
Chembiochem : a European Journal of Chemical Biology
|January 11, 2024
Summary
Molybdenum-copper antagonism, observed in metalloproteins and ruminants, involves tetrathiomolybdate (TTM) sequestering copper. This interaction inspires TTM
Area of Science:
- Biochemistry
- Metalloprotein Chemistry
- Medical Chemistry
Background:
- Molybdenum-copper (Mo-Cu) antagonism is mediated by the "Mo-S-Cu" structural unit.
- This antagonism is exemplified in metalloproteins like Molybdenum/Copper-CO Dehydrogenases (Mo/Cu-CODH) and Molybdenum/Copper Orange Proteins (Mo/Cu-ORP).
- Naturally occurring Mo-Cu antagonism was first identified in ruminants, where molybdate is converted to tetrathiomolybdate (TTM), leading to copper deficiency.
Purpose of the Study:
- To explore the structure-function relationship of Mo-Cu antagonism in biological systems.
- To connect the understanding of Mo-Cu antagonism in metalloproteins with its therapeutic potential.
- To review the application of TTM as an anti-copper therapeutic agent for copper-dependent diseases.
Main Methods:
- Review of existing literature on Mo-Cu antagonism in metalloproteins.
- Analysis of biological case studies, including Mo/Cu-CODH and Mo/Cu-ORP.
- Examination of the mechanism of TTM formation and its interaction with copper in biological systems.
Main Results:
- Mo-Cu antagonism plays a crucial role in metalloproteins and biological copper homeostasis.
- TTM formation in ruminants demonstrates a natural mechanism for copper sequestration.
- TTM's ability to form biologically unavailable Mo/S/Cu clusters highlights its potential as a copper-sequestering agent.
Conclusions:
- Mo-Cu antagonism is a significant biological interaction with implications for copper homeostasis.
- The study of Mo-Cu antagonism in metalloproteins provides insights into therapeutic strategies.
- Tetrathiomolybdate (TTM) shows promise as a therapeutic agent for treating copper-related diseases like Wilson disease and cancer.
Related Concept Videos
00:56Extraction: Advanced Methods
447
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
447
01:30Combined Effects of Drugs: Antagonism
8.5K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.5K
01:17Antidotes
649
Antidotes are medicinal substances used to counteract the harmful effects of toxins or drugs in the body. They function in various ways, each uniquely designed to combat specific toxic compounds.
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
649
01:46Electron Transport Chain: Complex I and II
13.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.4K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
01:24Mania and Antimanic Drugs: Overview
184
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
184